Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G protein-coupled estrogen receptor (GPER), also known as GPR30 or GPER1, is a seven-transmembrane domain receptor and member of the GPCR family. It binds with high affinity to 17β-estradiol (E2) and mediates rapid non-genomic signaling events, activating pathways like cAMP/PKA, PLC/IP₃/Ca²⁺, PI3K/Akt, and MAPKs. GPER is expressed in various tissues, playing roles in cardiovascular regulation, immune modulation, and metabolic regulation. It is implicated in diseases such as cancer, cardiovascular disorders, and metabolic disorders, making it a therapeutic target for selective agonists/antagonists.
Agonists and antagonists modulate GPER activity, impacting downstream signaling pathways such as cAMP/PKA, PLC/IP₃/Ca²⁺, PI3K/Akt, and MAPKs. This leads to rapid non-genomic effects and modulation of gene expression.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-coupled estrogen receptor (GPER).